Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

150.87 -2.56 (-1.67%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Guardant Health (GH) Q3 2026 Earnings Call Transcript ↗
Shield cost per test beat its target early while screening guidance moved higher. 
Via The Motley Fool
Topics Earnings
News headline image
GH Q3 2026 deep dive: new product launches and coverage wins drive growth, but market cautious on profitability
Diagnostics company Guardant Health (NASDAQ:GH) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 36.1% year on year to $36... 
Via StockStory
News headline image
1 healthcare stock to research further and 2 we avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have... 
Via StockStory
Guardant Health Inc (NASDAQ:GH) Falls 12% Despite In-Line Q3 Revenue as Guidance Disappoints ↗
Via Chartmill
News headline image
What Guardant Health (GH) Said on Its Q3 Earnings Call ↗
Guardant Health (NASDAQ:GH) raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Guardant Health’s (NASDAQ:GH) Q3 2026 sales beat estimates but stock drops 10.2%
Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 36.1% year on year to $361 million. The c... 
Via StockStory
Topics Earnings
News headline image
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health earnings: what to look for from GH
Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings this Thursday after the bell. Here’s what to expect. Guardant Health beat analysts... 
Via StockStory
Topics Artificial Intelligence
News headline image
Kevin Sayer Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Reasons GH is risky and 1 stock to buy instead
What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 93.5%, hitting $171.24. This was partly due to its solid qu... 
Via StockStory
Topics Bankruptcy Supply Chain
News headline image
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning ↗
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
From Guardant Health, Inc.
Via Business Wire
News headline image
3 of Wall Street’s Favorite Stocks That Fall Short
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
From Guardant Health, Inc.
Via Business Wire
News headline image
3 Cash-Burning Stocks with Questionable Fundamentals
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy Supply Chain
News headline image
1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Question
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
Topics Credit Cards
News headline image
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) a... 
Via StockStory
News headline image
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Business Insider Names Guardant Health One of America's Most Innovative Businesses
From Guardant Health, Inc.
Via Business Wire
News headline image
1 Growth Stock to Add to Your Roster and 2 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
From Guardant Health, Inc.
Via Business Wire
News headline image
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
News headline image
Why Rule Breakers Buy a Stock That's Already "Won" ↗
You found a great company, then watched it double before you got round to buying. 
Via The Motley Fool
Topics Death
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback